Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | AHCY | P23526 | 4/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.33 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | SCARB1 | Q8WTV0 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1025169 | 0.88 | NPY2R (0.37) | AHCYNPY2RACKR3PDK2TP53 | |
| SCHEMBL1025761 | 0.87 | AHCY (0.35) | AHCYUSP30 | |
| SCHEMBL1028289 | 0.85 | AHCY (0.38) | AHCY | |
| SCHEMBL1026020 | 0.84 | RBP4 (0.36) | AHCY | |
| SCHEMBL11976141 | 0.82 | AHCY (0.53) | AHCYNPY2R | |
| SCHEMBL11976131 | 0.81 | AHCY (0.44) | AHCYNPY2RCYP2C9 | |
| SCHEMBL1028593 | 0.80 | AHCY (0.39) | AHCY | |
| SCHEMBL1027641 | 0.79 | FNTA (0.39) | GPR119AHCY | |
| SCHEMBL1028770 | 0.76 | NPY2R (0.36) | GPR119AHCYUSP30NPY2RTBK1 | |
| SCHEMBL11967239 | 0.76 | AHCY (0.53) | AHCYNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2486925-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | GPR119 644/4885AHCY 4108/4885USP30 4033/4885 |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | BHMT, CBS, BHMT2 | GPR119 2613/4885AHCY 4/4885USP30 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.